Clinical Trials Logo

Ineffective Erythropoiesis clinical trials

View clinical trials related to Ineffective Erythropoiesis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05880030 Completed - Healthy Clinical Trials

The Effect of Supplementation of Vitamin D3 on Inflammation Induced by 100 km Running, Iron Metabolism and Erythropoiesis

Start date: October 19, 2016
Phase: N/A
Study type: Interventional

A group of runners received vitamin D (10,000 IU - international unit per day) for two weeks. The aim of the intervention was to check the effect of vitamin D supplementation on selected parameters of inflammation and iron metabolism in comparison with the placebo group. Blood was collected before and after supplementation. Next: before, after 25, 50, 75,100 km running and 12 hours after the run. The data were subjected to statistical analysis.

NCT ID: NCT04054921 Completed - ß-thalassemia Clinical Trials

Safety Study for Beta Thalassemia Subjects on PTG-300

TRANSCEND
Start date: May 10, 2019
Phase: Phase 2
Study type: Interventional

In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.

NCT ID: NCT03802201 Completed - ß-thalassemia Clinical Trials

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia

TRANSCEND
Start date: December 19, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort . The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment in β-thalassemia.

NCT ID: NCT02134119 Completed - Clinical trials for Ineffective Erythropoiesis

Echinacea-based Supplement Does Not Improve Markers of Performance in Athletes

Start date: January 2012
Phase: N/A
Study type: Interventional

The purpose of this study was three-fold. We wanted to (1) determine if supplementation with an echinacea-based dietary supplement (ECH) would increase several blood parameters that could affect oxygen carrying capacity in the body, (2) determine if ECH would increase VO2max in trained endurance athletes, and (3) examine the effectiveness of two different doses of the ECH on all outcome variables. We hypothesized that supplementation with ECH would increase oxygen carrying capacity (as measured by RBCs, EPO, ferritin, hemoglobin (Hb), and hematocrit (Hct) levels), improve VO2max, and that the maximum dose would be most effective at increasing these outcomes.